TradePress Releases
Public Ventures, LLC and the companies it backs make the news because of their revolutionary approaches to solving global challenges. If you have needs beyond these resources, please contact [email protected].
MDB Capital Holdings to Host Fourth Quarter 2023 and Fiscal Year 2023 Results Webinar on Wednesday April 17, 2024 at 4:30 PM Eastern Time
Addison, Texas, Apr. 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, plans to...
Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
Monrovia, CA, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB") – today announced it has filed a registration statement on...
MDB Capital Holdings Issues Annual Letter to Shareholders
January 31, 2024 Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) ("MDB"), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and...
MDB Capital Holdings to Host Third Quarter 2023 Results Conference Call on November 15, 2023 at 4:30 PM Eastern Time
November 2, 2023 Addison, TX, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) ("MDB"), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and...
Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort
Non-Dilutive Funding and Resources Provided to De-Risk Investment and Accelerate Commercialization October 17, 2023 10:00 ET| Source: Invizyne Technologies, Inc. Monrovia, CA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of...
Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy
Funding Supports Project to Optimize and Scale Up Isobutanol Production to Address Potential $27.4 Billion Sustainable Aviation Fuel Market October 11, 2023 11:10 ET| Source: Invizyne Technologies, Inc. Monrovia, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Invizyne...
Public Ventures LLC Officially Granted DTC and NSCC Approval as a Self-Clearing Broker Dealer
DALLAS, TX / ACCESSWIRE / June 15, 2023 / Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, today announced it received official approval on May 31 to become both a Participant as set forth by the rules, by-laws and organization certificate...
HeartBeam Completes $25 Million Capital Raise and Updates 2023 Strategic Focus and Financial Guidance
HeartBeam to Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Funding to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones, Extends Cash Runway into Late 2024...
MDB Capital Holdings Announces Third MDB-Launched Company to Achieve FDA Approval
DALLAS, T.X. / ACCESSWIRE / November 29, 2022 / MDB Capital Holdings, LLC, a privately-held public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today announced that...
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
DALLAS, TX / ACCESSWIRE / November 17, 2022 / Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, completed its first financing as a broker-dealer for Cue Biopharma, Inc. (NASDAQ:CUE). The Public Ventures' portion of the financing was...
Up Next